Mono Pharmacare LimitedMONOPHARMACorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Sep 2025 6 quarters of data

₹8.90

MCap ₹16 Cr · P/E 15.7

Mono Pharmacare Limited — Stock analysis & AI research Mono Pharmacare Limited — Seasonality — best & worst months Mono Pharmacare Limited — Live exchange announcements

🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹66 Cr

Sales · Sep 2025

-24.1% YoY

₹2 Cr

Operating Profit · Sep 2025

-60.0% YoY

3.0%

OPM % · Sep 2025

-47.4% YoY

₹0 Cr

Net Profit · Sep 2025

-100.0% YoY

₹0.01

EPS · Sep 2025

-99.2% YoY

📝 Mono Pharmacare Limited — results explained

Quarter ended September 2025 (Q2 FY26)

Mono Pharmacare Limited reported revenue of ₹66 crore for the quarter ended September 2025 (Q2 FY26), down 24.1% from ₹87 crore in the same quarter last year.

Net profit fell 100.0% year-on-year to ₹0 crore, from ₹2 crore. Earnings per share (EPS) came in at ₹0.01.

Operating profit stood at ₹2 crore — an operating margin (OPM) of 3.0%, compared with 5.7% in the year-ago quarter.

Full year and trailing twelve months

On a trailing-twelve-month (TTM) basis, revenue stands at ₹147 crore with a net profit of ₹1 crore.

Valuation snapshot

At the current price of ₹8.90, MONOPHARMA has a market capitalisation of ₹16 crore and a trailing P/E of about 15.7.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 25th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Sep 2025, promoters held 56.72%, public shareholders 43.28% of Mono Pharmacare Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹16 Cr

Current Price ?

₹8.9

P/E ?

15.73below ind

Industry P/E ?

37.20

P/B ?

0.49

P/S ?

0.11

P/FCF ?

-3.15

Enterprise Value ?

₹71 Cr

EV/EBITDA ?

14.15

PEG ?

N/A

Earnings Yield ?

7.1%

Dividend Yield ?

0.00%

Profitability & Returns

Sales (TTM) ?

₹147 Cr

OPM ?

3.4%

Profit after tax (TTM) ?

₹1 Cr

EPS (TTM) ?

₹0.57

ROCE ?

11.0%

ROE ?

3.1%

ROA ?

0.8%

Growth

Sales — latest qtr ?

₹66 Cr

PAT — latest qtr ?

₹0 Cr

YoY qtr sales growth ?

-24.1%

YoY qtr profit growth ?

-100.0%

Sales growth (3y) ?

N/A

Sales growth (5y) ?

N/A

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

₹55 Cr

Debt to Equity ?

1.72

Interest Coverage ?

N/A

Current Ratio ?

N/A

Ownership

Promoter holding ?

56.72%

Change in promoter holding ?

0.00%

Pledged percentage ?

N/A

Market

Return 3 months ?

-19.1%

Return 6 months ?

-26.4%

🗓️ Quarterly results (6 quarters · ₹ Cr)

same fiscal quarter as Sep bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Mar 2023	Sep 2023	Mar 2024	Sep 2024	Mar 2025	Sep 2025	YoY %	QoQ %
Sales	35	67	56	87	81	66	-24.1%	—
Operating Profit	2	4	2	5	3	2	-60.0%	—
Other Income	0	0	0	0	1	0	—	—
Interest	1	2	2	2	2	2	+0.0%	—
Depreciation	0	0	0	0	0	0	—	—
Profit Before Tax	1	2	1	3	1	0	-100.0%	—
Net Profit	1	2	1	2	1	0	-100.0%	—
EPS	0.52	1.06	0.33	1.30	0.46	0.01	-99.2%	—
OPM %	5.7%	6.0%	3.6%	5.7%	3.7%	3.0%	-47.4%	—

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Sep 2025	% Chg
Equity Capital	12	18	18	18	+0.0%
Reserves	1	10	14	14	+0.0%
Borrowings	40	41	54	55	+1.9%
Other Liabilities	9	12	25	33	+32.0%
Total Liabilities	63	81	110	119	+8.2%
Fixed Assets	1	1	1	1	+0.0%
CWIP	0	0	0	0	—
Investments	1	0	0	0	—
Other Assets	61	80	109	118	+8.3%
Total Assets	63	81	110	119	+8.2%

💧 Cash Flow (latest 3 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	% Chg
Cash from Operating Activity	-28	-9	-4	+55.6%
Cash from Investing Activity	-1	0	-0	—
Cash from Financing Activity	30	8	5	-37.5%
Net Cash Flow	0	-0	0	—
Free Cash Flow	-29	-9	-5	+44.4%
CFO/OP	-1,826%	-127%	-38%	+70.1%

➗ Ratios (latest 3 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	% Chg
Debtor Days	296	94	91	-3.2%
Inventory Days	497	139	133	-4.3%
Days Payable	103	32	45	+40.6%
Cash Conversion Cycle	689	202	179	-11.4%
Working Capital Days	399	131	120	-8.4%
ROCE %	—	10%	11%	+10.0%

👥 Shareholding (latest 4 periods)

Metric	Mar 2024	Sep 2024	Mar 2025	Sep 2025	% Chg
Promoters	56.72%	56.72%	56.72%	56.72%	+0.0%
Public	43.28%	43.28%	43.28%	43.28%	+0.0%
No. of Shareholders	418	463	478	514	+7.5%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	AKUMS Akums Drugs	₹784.55	12,012	41.2	4,502	293	12.6%	6.5%	5.9%	-25.5%	13.9%	56.1%
2	STAR Strides Pharma	₹1,085.00	10,001	26.7	3,636	389	25.4%	10.7%	-20.4%	99.0%	11.2%	50.0%
3	BLUEJET Blue Jet	₹565.05	9,802	36.9	884	265	36.3%	30.0%	8.0%	0.7%	-17.5%	-14.3%
4	AARTIPHARM Aarti Pharmalabs	₹828.30	7,511	36.1	1,957	208	22.0%	10.6%	1.5%	-26.9%	42.4%	39.2%
5	SUPRIYA Supriya Lifescience	₹870.30	7,004	35.3	873	198	33.2%	22.7%	18.9%	11.1%	30.8%	-30.9%
6	INNOVACAP Innova Captab	₹1,199.30	6,863	13.8	5,779	497	14.6%	8.6%	355.1%	277.4%	33.9%	42.3%
7	MOREPENLAB Morepen Laboratories	₹123.35	6,759	48.0	1,951	141	9.4%	7.2%	-0.3%	-18.3%	34.1%	394.0%
8	IOLCP IOL Chemicals	₹201.19	5,905	35.2	2,523	168	12.3%	6.7%	11.5%	36.6%	37.1%	89.8%
9	FDC FDC	₹350.20	5,702	19.5	2,191	291	15.3%	13.3%	3.0%	4.8%	3.0%	9.5%
10	NOVARTIND Novartis India	₹2,257.80	5,575	57.0	371	97	27.6%	26.2%	-0.3%	-6.9%	18.2%	14.3%
11	ORCHPHARMA Orchid Pharma	₹1,058.75	5,370	236.9	812	22	5.1%	2.7%	-11.9%	-76.4%	0.2%	25.4%
12	RPGLIFE RPG Life	₹2,865.90	4,740	39.7	735	120	21.1%	16.3%	8.4%	-36.9%	15.8%	16.3%
13	ZOTA Zota Health	₹1,232.70	4,269	—	609	-104	0.6%	-17.1%	84.6%	-29.8%	66.9%	-213.9%
14	GUFICBIO Gufic Biosciences	₹419.85	4,210	57.3	974	74	16.9%	7.6%	14.7%	-9.1%	14.9%	86.0%
15	UNICHEMLAB Unichem Laboratories	₹526.70	3,708	12.2	2,308	305	9.9%	13.2%	6.2%	74.1%	20.1%	496.1%
16	INDSWFTLAB Ind-Swift Laboratories	₹374.00	3,252	55.4	665	57	9.0%	8.6%	235.3%	10.1%	32.3%	-88.7%
17	ADVENZYMES Advanced Enzyme	₹293.25	3,249	19.8	750	172	29.8%	22.9%	17.1%	29.6%	2.1%	-4.6%
18	SOLARA Solara Active	₹667.00	3,218	85.6	1,535	37	15.2%	2.4%	6.6%	-1470.4%	33.1%	381.8%
19	DCAL Dishman Carbogen	₹162.08	2,541	157.6	2,902	16	16.7%	0.6%	8.1%	2655.7%	-4.3%	-351.7%
20	INDOCO Indoco Remedies	₹254.59	2,347	n/m	1,872	3	8.8%	0.2%	10.7%	-26.5%	6.5%	280.0%
21	PANACEABIO Panacea Biotec	₹368.55	2,257	—	673	-9	0.3%	-1.3%	14.4%	17.9%	19.7%	-44.4%
22	REMUS Remus Pharma.	₹1,911.30	2,252	91.1	94	25	31.7%	26.7%	—	—	13.3%	21.4%
23	SAKAR Sakar Healthcare	₹987.40	2,167	61.0	272	36	28.5%	13.3%	41.9%	71.8%	38.4%	120.2%
24	JAGSNPHARM Jagsonpal Pharmaceuticals	₹227.53	1,501	33.3	294	45	20.7%	15.4%	6.9%	-22.2%	8.5%	20.4%
25	MONOPHARMA Mono Pharmacare	₹40.85	72	88.8	147	1	3.4%	0.7%	—	—	-24.1%	-100.0%

❓ Frequently asked questions

What was Mono Pharmacare Limited's revenue in Q2 FY26?